SubsidieMeestersPrefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell Culture
The Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials.
Projectdetails
Introduction
In 2020, the cell culture market was valued at $19 billion USD, with consumables comprising more than 60% of the market. The emerging 3D cell culture provides lucrative business opportunities for consumables and tissue test models. However, current technology and market supply lack an easy and reliable tool for the uncomplicated creation and cultivation of vascularized and perfusable artificial 3D tissue.
Current Market Limitations
The current 3D cell culture consumable market offers only well plate inserts and organ-on-a-chip systems for generating 3D tissues, which are limited regarding tissue mimicry and complexity. Bioprinting, while promising, is still unreliable for reproducible vascularized tissue engineering.
Project Overview
The EIC Transition Proposal Vasc-on-Demand aims to fill this gap by providing three easy-to-use laboratory products for the generation and cultivation of perfusable vascularized 3D tissue:
- BasicVasc: An all-in-one bioreactor consumable for generation and cultivation of perfusable tissue culture.
- EasyVasc: Prefabricated ready-to-use vessel channel networks without cells.
- CompleteVasc: Prefabricated matured cell-containing vascularization.
Product Development
EasyVasc and CompleteVasc both build on the BasicVasc technology. Therefore, BasicVasc will be advanced for high-throughput production of precisely manufactured structures to be ready for the market. The other products will be fully developed and characterized to allow improved vascularized tissue production with even more advanced and simpler ready-to-use systems.
Team and Goals
This grant will be carried out by a highly motivated team with synergistic expertise in technology, product engineering, and business development, working towards the foundation of a start-up for the commercialization of the technology.
Potential Impact
The proposed Vasc-on-Demand has the potential to simplify the development of sophisticated test models for research and pharmaceutical approaches like drug testing, leading to reduced animal trials and development costs.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.488.750 |
| Totale projectbegroting | € 2.488.750 |
Tijdlijn
| Startdatum | 1-5-2024 |
| Einddatum | 30-4-2027 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITATpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Dypha: adding the dimension of time to cell cultureThe δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models. | EIC Transition | € 2.499.625 | 2024 | Details |
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to LabBiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening. | EIC Transition | € 2.500.000 | 2022 | Details |
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactorThe project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions. | EIC Transition | € 1.798.152 | 2022 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Dypha: adding the dimension of time to cell culture
The δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models.
Fully automated cell-free DNA extraction and quantification - liquid biopsies safely from Patient to Lab
BiopSense aims to develop and validate a fully automated disposable cartridge for cfDNA extraction from blood, enhancing reliability and transport ease for cancer diagnostics and prenatal screening.
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor
The project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Laser biofabrication of 3D multicellular tissue with perfusible vascular networkThis project aims to revolutionize organ regeneration by developing a 3D vascular system using advanced bioprinting techniques to enable effective perfusion in tissue constructs. | ERC Advanced... | € 2.499.539 | 2022 | Details |
VAScularised Tumour Organoids on a chip with human placenta vessels as a preclinical model for anticancer therapies.VASTO Proof of Concept develops a microfluidic platform using human ex vivo blood vessels to evaluate CAR-T cell therapies against solid tumors, aiming to enhance personalized cancer treatment and reduce animal testing. | ERC Proof of... | € 150.000 | 2023 | Details |
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughputHEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments. | ERC Consolid... | € 2.969.219 | 2022 | Details |
High-throughput ultrasound-based volumetric 3D printing for tissue engineeringSONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research. | EIC Pathfinder | € 2.999.625 | 2025 | Details |
Redesigning aortic endograft: enabling in-situ personalized aneurysm healingEPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models. | ERC Consolid... | € 1.991.225 | 2024 | Details |
Laser biofabrication of 3D multicellular tissue with perfusible vascular network
This project aims to revolutionize organ regeneration by developing a 3D vascular system using advanced bioprinting techniques to enable effective perfusion in tissue constructs.
VAScularised Tumour Organoids on a chip with human placenta vessels as a preclinical model for anticancer therapies.
VASTO Proof of Concept develops a microfluidic platform using human ex vivo blood vessels to evaluate CAR-T cell therapies against solid tumors, aiming to enhance personalized cancer treatment and reduce animal testing.
3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput
HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.
High-throughput ultrasound-based volumetric 3D printing for tissue engineering
SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.
Redesigning aortic endograft: enabling in-situ personalized aneurysm healing
EPEIUS aims to revolutionize aortic aneurysm treatment by developing a bioengineered, 3D-printed, drug-loaded endograft for early personalized healing through innovative in-vitro models.